Agilent Technologies (NYSE:A) Downgraded by Wolfe Research to Peer Perform

Wolfe Research downgraded shares of Agilent Technologies (NYSE:A) from an outperform rating to a peer perform rating in a research note published on Thursday morning, Marketbeat reports.

A has been the topic of a number of other research reports. Barclays cut their price objective on shares of Agilent Technologies from $135.00 to $125.00 and set an underweight rating on the stock in a research report on Friday, May 31st. Oppenheimer increased their price objective on shares of Agilent Technologies from $67.00 to $90.00 and gave the stock an outperform rating in a research report on Tuesday, March 26th. Robert W. Baird dropped their target price on Agilent Technologies from $147.00 to $136.00 and set an outperform rating for the company in a research report on Thursday, May 30th. JPMorgan Chase & Co. reduced their price target on Agilent Technologies from $165.00 to $155.00 and set an overweight rating on the stock in a report on Thursday, May 30th. Finally, TD Cowen dropped their price objective on Agilent Technologies from $163.00 to $153.00 and set a buy rating for the company in a report on Thursday, May 30th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the company. According to MarketBeat, Agilent Technologies currently has a consensus rating of Hold and a consensus price target of $136.88.

Agilent Technologies Trading Down 0.9 %

A stock opened at $129.63 on Thursday. The firm has a fifty day moving average price of $139.56 and a 200 day moving average price of $138.47. Agilent Technologies has a fifty-two week low of $96.80 and a fifty-two week high of $155.35. The firm has a market cap of $37.82 billion, a PE ratio of 30.65, a price-to-earnings-growth ratio of 4.44 and a beta of 1.07. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.64 and a current ratio of 2.15.

Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Wednesday, May 29th. The medical research company reported $1.22 EPS for the quarter, topping analysts’ consensus estimates of $1.19 by $0.03. The business had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Agilent Technologies had a net margin of 18.84% and a return on equity of 26.25%. The business’s revenue was down 8.4% on a year-over-year basis. During the same period last year, the company posted $1.27 EPS. Sell-side analysts anticipate that Agilent Technologies will post 5.25 earnings per share for the current fiscal year.

Agilent Technologies Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 24th. Stockholders of record on Tuesday, July 2nd will be given a $0.236 dividend. The ex-dividend date of this dividend is Tuesday, July 2nd. This represents a $0.94 dividend on an annualized basis and a dividend yield of 0.73%. Agilent Technologies’s payout ratio is 22.22%.

Insider Activity at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,958 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $130.00, for a total transaction of $254,540.00. Following the transaction, the chief executive officer now owns 25,185 shares in the company, valued at approximately $3,274,050. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Agilent Technologies news, SVP Dominique Grau sold 15,000 shares of Agilent Technologies stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $133.28, for a total transaction of $1,999,200.00. Following the completion of the transaction, the senior vice president now owns 49,486 shares in the company, valued at approximately $6,595,494.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $130.00, for a total transaction of $254,540.00. Following the sale, the chief executive officer now directly owns 25,185 shares in the company, valued at approximately $3,274,050. The disclosure for this sale can be found here.

Hedge Funds Weigh In On Agilent Technologies

Several institutional investors and hedge funds have recently modified their holdings of A. EverSource Wealth Advisors LLC raised its position in Agilent Technologies by 36.4% during the first quarter. EverSource Wealth Advisors LLC now owns 731 shares of the medical research company’s stock worth $100,000 after acquiring an additional 195 shares during the period. Cambridge Trust Co. lifted its stake in Agilent Technologies by 4.5% in the 1st quarter. Cambridge Trust Co. now owns 110,305 shares of the medical research company’s stock valued at $16,051,000 after buying an additional 4,736 shares in the last quarter. Cetera Advisors LLC boosted its holdings in Agilent Technologies by 45.7% in the 1st quarter. Cetera Advisors LLC now owns 13,620 shares of the medical research company’s stock worth $1,982,000 after buying an additional 4,274 shares during the last quarter. Cetera Investment Advisers increased its stake in Agilent Technologies by 953.3% during the 1st quarter. Cetera Investment Advisers now owns 32,694 shares of the medical research company’s stock worth $4,757,000 after buying an additional 29,590 shares in the last quarter. Finally, PGGM Investments increased its stake in Agilent Technologies by 10.9% during the 1st quarter. PGGM Investments now owns 27,431 shares of the medical research company’s stock worth $3,991,000 after buying an additional 2,699 shares in the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.